B cell reconstitution and T helper cell balance after rituximab treatment of active primary Sjögren's syndrome: a double-blind, placebo-controlled study

Arthritis Rheum. 2011 Apr;63(4):1116-23. doi: 10.1002/art.30236.
No abstract available

Publication types

  • Randomized Controlled Trial
  • Research Support, Non-U.S. Gov't

MeSH terms

  • Adult
  • Antibodies, Monoclonal, Murine-Derived / pharmacology
  • Antibodies, Monoclonal, Murine-Derived / therapeutic use*
  • Antirheumatic Agents / pharmacology
  • Antirheumatic Agents / therapeutic use
  • B-Lymphocytes / drug effects
  • B-Lymphocytes / metabolism
  • B-Lymphocytes / pathology*
  • CD4-Positive T-Lymphocytes / drug effects
  • CD4-Positive T-Lymphocytes / metabolism
  • CD4-Positive T-Lymphocytes / pathology
  • Cell Count
  • Double-Blind Method
  • Female
  • Humans
  • Immunoglobulin D / metabolism
  • Immunoglobulin M / metabolism
  • Male
  • Middle Aged
  • Rituximab
  • Sjogren's Syndrome / drug therapy*
  • Sjogren's Syndrome / metabolism
  • Sjogren's Syndrome / pathology*
  • T-Lymphocytes, Helper-Inducer / drug effects
  • T-Lymphocytes, Helper-Inducer / metabolism
  • T-Lymphocytes, Helper-Inducer / pathology*
  • Time Factors
  • Tumor Necrosis Factor Receptor Superfamily, Member 7 / metabolism

Substances

  • Antibodies, Monoclonal, Murine-Derived
  • Antirheumatic Agents
  • Immunoglobulin D
  • Immunoglobulin M
  • Tumor Necrosis Factor Receptor Superfamily, Member 7
  • Rituximab